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New Spirometry Indices for 
Detecting Mild Airflow Obstruction
Surya P. Bhatt1,2, Nirav R. Bhakta3, Carla G. Wilson4, Christopher B. Cooper5, 
Igor Barjaktarevic5, Sandeep Bodduluri1,2, Young-il Kim1,6, Michael Eberlein7, 
Prescott G. Woodruff3, Frank C. Sciurba8, Peter J. Castaldi9, MeiLan K. Han10, 
Mark T. Dransfield1,2 & Arie Nakhmani  11
The diagnosis of chronic obstructive pulmonary disease (COPD) relies on demonstration of airflow 
obstruction. Traditional spirometric indices miss a number of subjects with respiratory symptoms or 
structural lung disease on imaging. We hypothesized that utilizing all data points on the expiratory 
spirometry curves to assess their shape will improve detection of mild airflow obstruction and structural 
lung disease. We analyzed spirometry data of 8307 participants enrolled in the COPDGene study, and 
derived metrics of airflow obstruction based on the shape on the volume-time (Parameter D), and flow-
volume curves (Transition Point and Transition Distance). We tested associations of these parameters 
with CT measures of lung disease, respiratory morbidity, and mortality using regression analyses. 
There were significant correlations between FEV1/FVC with Parameter D (r = −0.83; p < 0.001), 
Transition Point (r = 0.69; p < 0.001), and Transition Distance (r = 0.50; p < 0.001). All metrics had 
significant associations with emphysema, small airway disease, dyspnea, and respiratory-quality of 
life (p < 0.001). The highest quartile for Parameter D was independently associated with all-cause 
mortality (adjusted HR 3.22,95% CI 2.42–4.27; p < 0.001) but a substantial number of participants in the 
highest quartile were categorized as GOLD 0 and 1 by traditional criteria (1.8% and 33.7%). Parameter 
D identified an additional 9.5% of participants with mild or non-recognized disease as abnormal with 
greater burden of structural lung disease compared with controls. The data points on the flow-volume 
and volume-time curves can be used to derive indices of airflow obstruction that identify additional 
subjects with disease who are deemed to be normal by traditional criteria.
The clinical diagnosis of chronic obstructive pulmonary disease (COPD) is based on the spirometric detection 
of airflow obstruction1. Approximately one-half of subjects without airflow obstruction by traditional spiromet-
ric criteria have substantial respiratory impairment or have structural lung disease on computed tomography 
(CT)2,3. These symptomatic smokers are also at increased risk of greater lung function decline and developing 
overt airflow obstruction on follow-up4. These findings point to the lack of sensitivity of traditional spirometric 
measures in detecting mild disease, and there is a need to develop novel metrics for the detection of mild airflow 
obstruction5.
The diagnosis of airflow obstruction currently relies on using fixed portions of the flow-volume curve that 
are not sensitive to detecting small airway disease. Previous attempts to detect mild small airways involvement 
have mostly relied on estimating the flow in the middle part of the flow-volume curve, examining the shape of 
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a segment of the curve visually or through automated analyses6–13, or by examining the change in the angle of 
flow during forced exhalation14,15. Although these measures showed promising results, the results were limited 
by small sample sizes and lack of validation against structural lung disease. We hypothesized that mathematical 
modeling using all the data points on the expiratory curves to assess their shape would enable derivation of indi-
ces of airflow obstruction that improve detection of mild airflow obstruction as well as structural disease on CT.
Methods
Study population. We analyzed spirometry data of subjects enrolled in the Genetic Epidemiology of COPD 
(COPDGene) study, a large multicenter cohort that included current and former smokers aged 45–80 years; study 
details have been previously published16. All participants underwent extensive phenotyping with spirometry17, 
CT imaging, and assessment of respiratory morbidity using questionnaires and the six minute walk test (details 
in Supplement). Participants were followed every 6 months to ascertain vital status. All participants provided 
written informed consent prior to study enrollment and the COPDGene study was approved by the University of 
Alabama at Birmingham IRB for Human Use (F070712014) and the institutional review boards of all 21 partici-
pating centers (Details in Supplement). All assessments and analyses were performed in accordance with relevant 
guidelines and regulations.
CT Metrics. Volumetric CT scans were obtained at maximal inspiration (total lung capacity, TLC) and 
end-tidal expiration (functional residual capacity, FRC). Emphysema and gas trapping were quantified using 3D 
Slicer software (www.airwayinspector.org), and Apollo Software (VIDA Diagnostics, Coralville, IA, USA) was 
used to measure airway dimensions16. Mild emphysema was quantified by using the percentage of lung volume 
at TLC with attenuation less than −910 Hounsfield Units (HU) (low attenuation area, %LAA910insp), and severe 
emphysema by %LAA < −950 HU16. We quantified gas trapping as the percentage of lung volume at end expira-
tion with attenuation less than −856 HU16. We used Wall area percentage of segmental airways (Wall area pct) to 
quantify airway disease16. In addition, we used parametric response mapping to match inspiratory and expiratory 
images voxel-to-voxel, and calculated the percentage of non-emphysematous gas trapping, or functional small 
airways disease (PRMfSAD), a measure of small airways disease18.
New Spirometry Metrics: Basis and Derivation. We used post-bronchodilator values for all analy-
ses, and the effort with the highest value for the forced expiratory volume in the first second (FEV1) and the 
forced vital capacity (FVC) was selected for analyses per the American Thoracic Society (ATS) criteria17,19. Using 
advanced computational tools, we analyzed the individual data points in the flow-volume and volume-time 
curves (volume measurements collected every 60 msec and flow measurements every 30 ml), and developed the 
following metrics to quantify important transition points and contours in the expiratory curves.
Shape of the volume-time curve. We used the Levenberg-Marquardt algorithm to fit the following model to 
the volume-time curve:Vestimated = AeBt + CeDt where A, B, C, D are the parameters found by the function fitting 
optimization process minimizing J = ||Vmeasured − AeBt − CeDt|| cost function. To differentiate between the AeBt 
and CeDt terms, we always assume that A > 0 and C < 0. The first term, AeBt, represents the rising slope of volume 
increase closer to the end of the exhalation, and the second term, CeDt, describes the overall volume-time curve, 
where Parameter D describes the rate of volume increase. Figure 1 shows an example of such a function fit. The 
code for computing Parameter D is available in the Supplement.
Transition Point. We defined the transition point by fitting a piecewise function with two linear segments 
to the flow-volume curve, where the data before the peak expiratory flow is ignored (see Fig. 2A). A nonlin-
ear least-squares algorithm was used to find the optimal fit parameters of the curve (x1, y1),(x2, y2),(x3, y3). The 
Transition Point is defined as x2.
Figure 1. Model fitting of the Volume-time curve.
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Transition Distance. Given the Transition Point is not always readily apparent even with computational tools as 
the slopes may not fit on linear regression lines, we refined this process by fitting an inverted parabola around the 
peak point using a least squares minimization algorithm (see Fig. 2B). The breaking point between the parabola 
and the rest of the curve was defined as the latest sample that still provided goodness of fit of at least R2 > 0.96. 
The Transition Distance is the distance on the X-axis (in ml) from the peak of the fitted parabola to the breaking 
point (Fig. 2B).
Details on the physiologic basis for the derivation of the new metrics are described in the Supplement.
Case definitions. COPD was defined by FEV1/FVC < 0.7020. We excluded participants with Preserved Ratio 
Impaired SpiroMetry (PRISm, FEV1/FVC > 0.70 but FEV1 < 80% predicted) to avoid confounding by restrictive 
processes21. Using data from non-smokers, we calculated the 90th percentile of normal for Parameter D (−0.104), 
and those greater than this threshold were deemed to have abnormal Parameter D. Those positive by both FEV1/
FVC and Parameter D were defined as having COPD, and those negative by both criteria were deemed to have 
no airflow obstruction. Subjects positive by Parameter D but negative by FEV1/FVC were defined as additional 
cases detected by Parameter D (Discordant COPD). We repeated all comparisons with COPD defined by FEV1/
FVC < 5th percentile of predicted value for age, sex, race and height (lower limit of normal, LLN) as having 
COPD-LLN (Results in Supplement)17,22. Similarly, those <10th percentile of normal for Transition Point (17.0) 
and Transition Distance (30.0) were categorized to have airflow obstruction.
Statistical analyses. Receiver operating characteristic (ROC) analyses measured the accuracy of the new 
spirometry indices in comparison with FEV1/FVC for identifying thresholds of structural lung disease on CT (5% 
severe emphysema and 5% functional small airway disease or fSAD). Generalized linear regression models were 
used to test associations between the new spirometry metrics and structural lung disease as well as respiratory 
morbidity indices. To assess performance of the new metrics in those with mild disease, we compared charac-
teristics in those with GOLD stage 0 and 1 only, and tested concordance for diagnosis using FEV1/FVC < 0.70 
(or < LLN) versus abnormal spirometry by new indices. Comparisons were made between those concordant and 
discordant for airflow obstruction by traditional and new spirometry indices with smokers concordant for not 
having airflow obstruction, using Analysis of Variance (ANOVA). With “normal” smokers as the reference group, 
adjusted odds ratios for CT measures of structural lung disease were estimated in each group. Cox proportional 
hazards were calculated for mortality for each higher quartile of Parameter D with the lowest quartile as the ref-
erence. Statistical significance was set at a two-sided alpha of 0.05. All analyses were performed using Statistical 
Package for the Social Sciences (SPSS 24.0, SPSS Inc., Chicago, IL, USA).
Results
We first examined performance of the new metrics in 8307 participants with a full set of spirometry and CT 
data (see Supplemental Figure 7: CONSORT diagram). Mean age of participants was 60.0 (SD 9.1) years, and 
the cohort was comprised of 45.5% females and 31.1% African Americans. Parameter D, Transition point and 
Transition Distance could be calculated in 5532 (66.6%), 7960 (95.8%), and 7960 (95.8%) of expiratory curves. 
Parameter D ranged from −0.41 to 0.02, with more positive values indicating greater disease; Transition point 
ranged from 4.0 to 133.0 with lower values indicating worse disease; and Transition Distance ranged from 30.0 to 
2220.0, with lower values indicating worse disease. Wherever Parameter D could not be automatically calculated, 
due to divergence of the function fitting algorithm and needing manual intervention, or the goodness of model 
fit was too low, the curves were discarded. The cohort encompassed a range of severity of airflow obstruction with 
49.5%, 9.1%, 21.9%, 13.0%, and 6.5% with GOLD stages 0 through 4, respectively. Parameter D was progressively 
harder to calculate in more severe disease and could be calculated in 82%, 75%, 58%, 37% and 28%, respectively 
in participants with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 0 through 4. As more 
severe disease is easily detected using traditional spirometry criteria, we focused on those with mild airflow 
obstruction in the second stage of analysis. In the overall cohort, there were significant correlations between 
FEV1/FVC and FEV1%predicted with Parameter D (r = −0.83; p < 0.001 and −0.66; p < 0.001, respectively), 
Figure 2. Computation of (A) the Transition Point, and (B). Computation of the breaking point and the change 
of volume from the maximum to the breaking point (Transition Distance).
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Transition Point (r = 0.69; p < 0.001 and 0.71; p < 0.001, respectively) and Transition Distance (r = 0.50; p < 0.001 
and 0.52; p < 0.001, respectively).
Association of New Metrics with Structural Lung Disease. Emphysema. Parameter D and FEV1/
FVC were similar in accuracy for identifying >5% severe emphysema (%LAA < −950 HU) (c-statistic 0.83,95% 
CI 0.82–0.84; p < 0.001, and 0.83,95% CI 0.81–0.84; p < 0.001, respectively), whereas the c-statistic for Transition 
Point, Transition Distance, and FEV1%predicted were 0.71 (95% CI 0.70–0.73; p < 0.001), 0.68 (95% CI 0.66–
0.69; p < 0.001), and 0.73 (95% CI 0.71–0.75; p < 0.001), respectively. Parameter D and FEV1/FVC also had 
comparable accuracy for identifying 10% severe emphysema (c-statistic 0.91,95%CI 0.89–0.92; p < 0.001, and 
0.91,95% CI 0.90–0.93; p < 0.001, respectively). For 10% emphysema, Transition Point, Transition Distance and 
FEV1%predicted had improved accuracies with c-statistic of 0.81 (95% CI 0.79–0.83; p < 0.001), 0.77 (95%CI 
0.75–0.79; p < 0.001), and 0.84 (95% CI 0.82–0.86; p < 0.001), respectively.
Small Airway Disease. Parameter D and FEV1/FVC were similar in accuracy for identifying >5% fSAD 
(c-statistic 0.76,95% CI 0.74–0.78; p < 0.001, and 0.78,95% CI 0.77–0.80; p < 0.001, respectively), whereas the 
c-statistic for Transition Point, Transition Distance, and FEV1%predicted were 0.63 (95% CI 0.61–0.64; p < 0.001), 
0.59 (95% CI 0.57–0.61; p < 0.001), and 0.66 (95% CI 0.65–0.68; p < 0.001), respectively.
Association of New Metrics with Outcomes. All three new metrics had significant associations with 
emphysema, small airway disease, medium size airway disease, as well as respiratory morbidity, after adjustment 
for age, sex, race, BMI, and scanner type for CT parameters (Table 1).
Association with Mortality. We had follow-up data on 7294 participants for a median (interquartile range, 
IQR) of 6.6 (5.8 to 7.3) years. 993 (12.0%) participants died on follow-up. Follow-up data was available in 4843 
(88%) of participants in whom Parameter D could be calculated. When subjects were categorized into quartiles 
of Parameter D, the higher two quartiles (≥−0.082 and −0.113 to −0.082) were associated with greater mortality 
compared with the lowest quartile (≤−0.142), unadjusted hazards ratio, HR 4.47,95% CI 3.42–5.85; p < 0.001 and 
1.41,95% CI 1.03–1.93; p = 0.031, respectively. After adjustment for age, sex, race and body-mass-index (BMI), 
only the highest quartile was significantly associated with mortality compared to the lowest quartile (adjusted HR 
3.22,95% CI 2.42–4.27; p < 0.001). Of note, there were a substantial number of participants in the highest quartile 
of Parameter D who were categorized as GOLD 0 and 1 by traditional criteria (1.8% and 33.7%, respectively). On 
the other hand, 90.3% and 99.3% of GOLD 3 and 4 in whom Parameter D could be measured were comprised of 
participants in the highest quartile of Parameter D. Mortality data for Transition Point and Transition Distance 
are shown in the Supplement.
Mild Disease
In the second stage of analysis, we focused on 4870 participants with GOLD stage 0 and 1. Mean age was 57.5 (SD 
8.6) years, and the subset was comprised of 46.4% females, and 37.7% African Americans. Both the Transition 
point and Transition Distance could be calculated in 4686 (96.2%) of expiratory curves whereas Parameter D 
could be calculated in 3930 (80.7%). 760/4870 (15.6%) had airflow obstruction by traditional GOLD criteria 
and 445/4870 (9.1%) using the LLN criteria for FEV1/FVC. 873/3930 (17.9%), 721/4686 (14.8%), and 788/4612 
(16.2%), respectively had airflow obstruction per Parameter D, Transition Point, and Transition Distance, 
respectively.
Comparison of Traditional Criteria and Parameter D. Table 2 shows a comparison of participants con-
cordant and discordant for abnormality by both FEV1/FVC < 0.70 and Parameter D. Parameter D identified an 
additional 9.5% of participants with mild or non-recognized disease as abnormal, and this proportion was 11.8% 
where Parameter D was calculable. Compared with participants who were concordant normal, these discordant 
cases positive by Parameter D alone were similar in age but with higher FEV1 and FVC as well as CT TLC and 
FRC, but had higher CT measures of emphysema, functional small airway disease as well as segmental bronchial 
wall thickness. These relationships held true after adjusting for age, sex, race, BMI, and CT scanner type (Table 3). 
Of the 465 discordant cases positive by Parameter D alone, more subjects had emphysema >5% (20.0% vs. 8.9%; 















% Emphysema 88.7 (84.9 to 92.6) 82.1 (78.0 to 86.2) −0.34 (−0.36 to −0.33) −0.33 (−0.34 to −0.31) −0.016 (−0.017 to −0.015) −0.014 (−0.015 to −0.013)
%PRMfSAD 176.7 (169.6 to 183.8) 153.5 (146.2 to 160.8) −0.53 (−0.55 to −0.51) −0.49 (−0.51 to −0.46) −0.023 (−0.025 to −0.022) −0.020 (−0.021 to −0.019)
WallArea% 21.2 (19.4 to 23.1) 30.1 (28.3 to 31.9) −0.094 (−0.099 to −0.090) −0.114 (−0.119 to −0.110) −0.004 (−0.005 to −0.004) −0.005 (−0.005 to −0.004)
SGRQ 157.5 (145.6 to 169.5) 206.5 (194.1 to 218.8) −0.70 (−0.73 to −0.67) −0.80 (−0.84 to −0.77) −0.034 (−0.036 to −0.032) −0.035 (−0.037 to −0.033)
mMRC 8.1 (7.4 to 8.9) 11.2 (10.4 to 12.0) −0.042 (−0.044 to −0.040) −0.045 (−0.047 to −0.043) −0.002 (−0.002 to −0.002) −0.002 (−0.002 to −0.002)
Table 1. Associations between New Metrics and CT disease and Respiratory Morbidity. *Adjusted for 
age, sex, race, and BMI as well as scanner type in the case of CT parameters. All p values were < 0.001. 
PRM = Parametric response mapping. fSAD = Functional small airway disease. SQRQ = St. George’s 
Respiratory Questionnaire. MMRC = Modified Medical Research Council Dyspnea Scale.
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p < 0.001) and PRMfSAD > 15% (43.4% vs. 26.5%; p < 0.001), compared with concordant normals. Of those pos-
itive by Parameter D alone, 115 (24.7%) and 91 (19.6%) had substantial symptoms as evidenced by St. George’s 
Respiratory Questionnaire (SGRQ) score >25 and modified Medical Research Council (mMRC) dyspnea score 
>2, respectively. Figure 3 shows a representative subject not detected by traditional criteria but had abnormal 
Parameter D.
“Normal” controls (Both 
FEV1/FVC and Parameter 
D negative) (n = 2896)
COPD (Both FEV1/
FVC and Parameter D 
positive) (n = 408)
FEV1/FVC Discordant 
(FEV1/FVC positive and 




D positive and FEV1/
FVC negative) (n = 465)
Demographics
Age (years) 56.5 (8.2) 61.4 (8.7)‡ 62.6 (9.3)‡ 56.8 (8.5)
Sex (%Males)‡ 51.8 63.5 49.1 65.8
Race (%White)‡ 57.9 82.1 73.9 71.4
BMI (kg/m2) 29.0 (5.8) 26.7 (5.1)‡ 27.3 (4.5)** 27.6 (5.2)‡
Pack-years 37.0 (20.1) 46.9 (25.8)‡ 43.1 (20.8)** 37.6 (18.2)
Spirometry
FEV1 (L) 2.90 (0.66) 2.76 (0.68)** 2.57 (0.61)‡ 3.06 (0.66)‡
FEV1 (%Pred) 98.1 (11.6) 90.9 (9.0)‡ 91.6 (9.3)‡ 95.6 (10.5)‡
FVC (L) 3.66 (0.85) 4.30 (1.02)‡ 3.87 (0.89)* 4.13 (0.91)‡
FEV1/FVC 0.80 (0.05) 0.64 (0.04)‡ 0.67 (0.03)‡ 0.74 (0.04)‡
Parameter D −0.14 (0.03) −0.08 (0.01)‡ −0.12 (0.02)‡ −0.09 (0.01)‡
Transition Point 37.8 (11.6) 32.1 (10.2)‡ 34.4 (11.3)** 35.0 (12.0)‡
Transition Point Distance 504.9 (217.8) 444.6 (187.7)‡ 484.8 (215.6) 487.2 (217.2)
CT
TLC (L) 5.2 (1.2) 6.4 (1.5)‡ 5.6 (1.3)** 6.0 (1.3)‡
FRC (L) 2.7 (0.7) 3.4 (0.9)‡ 3.1 (0.9)‡ 3.2 (0.8)‡
%Emphysema (LAA < −910insp) 16.2 (13.3) 30.1 (15.1)‡ 22.4 (14.9)‡ 23.5 (15.2)‡
Wall Area% 59.9 (2.9) 60.2 (2.8) 60.4 (2.7) 60.4 (2.9)**
% Severe Emphysema (LAA < −950insp) 0.5 (1.1) 2.7 (3.9)‡ 1.3 (2.3)‡ 1.0 (1.7)‡
% PRMfSAD 11.5 (10.0) 20.9 (10.7)‡ 18.7 (12.5)‡ 16.1 (11.6)‡
Respiratory Morbidity
MMRC 0.8 (1.2) 0.7 (1.1) 0.7 (1.1) 0.7 (1.2)
SGRQ 16.5 (17.7) 17.7 (17.0) 16.2 (16.9) 16.4 (17.4)
Table 2. Comparison of demographics, imaging and respiratory morbidity between concordant and discordant 
groups by Parameter D and FEV1/FVC < 0.70#. #COPD defined traditionally by FEV1/FVC < 0.70. *p < 0.05 
compared to “normal” controls. **p < 0.01 compared to “normal” controls. ‡p < 0.001 compared to “normal” 
controls. BMI = Body Mass Index. FEV1 = Forced Expiratory Volume in the first second. FVC = Forced Vital 
Capacity. TLC = Total Lung Capacity on computed tomography. FRC = Functional Residual Capacity on 
computed tomography. %LAA < 910insp = %Low Attenuation Area below a threshold of −910 Hounsfield 
Units at end inspiration. Wallarea% = Bronchial wall area at segmental level. PRM = Parametric response 
mapping. fSAD = Functional small airway disease. MMRC = Modified Medical Research Council Dyspnea 
Scale. SQRQ = St. George’s Respiratory Questionnaire.
Parameter
Mild Emphysema Emphysema PRMfSAD %Wall Area
Odds Ratio 95% CI p Odds Ratio 95% CI p Odds Ratio 95% CI p Odds Ratio 95% CI p
COPD 3.23 2.71 to 4.07 <0.001 6.97 5.45 to 8.92 <0.001 3.98 3.20 to 4.96 <0.001 1.91 1.57 to 2.32 <0.001
FVC-COPD 1.39 1.03 to 1.88 0.03 2.41 1.74 to 3.34 <0.001 2.24 1.64 to 3.08 <0.001 1.89 1.41 to 2.53 <0.001
Parameter D-COPD 1.92 1.59 to 2.31 <0.001 2.28 1.86 to 2.79 <0.001 2.01 1.65 to 2.45 <0.001 1.61 1.34 to 1.93 <0.001
Table 3. Odds Ratios of COPD diagnostic criteria for predicting imaging measures of COPD. Model 
adjusted for age, sex, race, BMI and scanner type. All comparisons made for each group in reference with 
normal controls. Mild emphysema defined by %LAA < −910 HU. PRM = Parametric response mapping. 
fSAD = Functional small airway disease. Wallarea% = Bronchial wall area at segmental level. CI = Confidence 
intervals COPD includes subjects positive by both criteria, FEV1/FVC < 0.70 and Parameter D > 90th percentile 
of normal. FVC-COPD includes subjects positive by FEV1/FVC < 0.70 only. Parameter D-COPD includes 
subjects positive by Parameter D > 90th percentile of normal only.
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Discussion
In a cohort of current and former smokers, we derived new indices of airflow obstruction that identify addi-
tional subjects with structural and clinical lung disease who are deemed to be normal by traditional criteria. 
These new metrics are independently associated with structural lung disease on CT, as well as with dyspnea and 
respiratory-quality of life, and are especially useful for subjects with borderline or mild disease by traditional 
criteria.
Traditional spirometry criteria are simple to use and perform well in detecting more apparent disease, but do 
miss a number of mild cases who might benefit from intervention. Parameter D identified a substantial number 
of additional asymptomatic and symptomatic patients who would otherwise be missed by the traditional criteria. 
The new metrics can also be used to identify subjects with mild disease with a high risk of mortality. Results from 
two large cohort studies have found that approximately one-half of participants without overt airflow obstruction 
using traditional criteria have substantial respiratory morbidity and structural changes on CT2,3. These sympto-
matic smokers are also at increased risk of greater lung function decline and developing overt airflow obstruction 
on follow-up4. These findings point to the lack of sensitivity of traditional spirometric measures in detecting mild 
disease. Our findings have important clinical implications. The utility of Parameter D lies not in supplanting 
existing spirometry measures, but in being able to find additional cases and hence increasing sensitivity for case 
finding. These new metrics can be easily adapted into commercially available spirometry software without any 
change in testing procedures to provide additional outputs that can help inform the likelihood of airflow obstruc-
tion in borderline cases. In cases where volume-time curves or flow-volume curves are sampled at frequencies 
different from our study, the curves can be resampled at the same rate as in our study and the codes shown in the 
Supplement applied.
Spirometric measures of airflow obstruction have mostly relied on utilizing fixed portions of the expira-
tory flow-volume curves, and have not seen major changes in decades. Although measures of FEV1/FVC and 
FEV1%predicted have stood the test of time, multiple recent studies suggest that these measures do not detect 
mild abnormalities detected by other methods such as plethysmography, diffusing capacity of the lung for carbon 
monoxide, and structural measures of disease on computed tomography23–25. Spirometric measures of small air-
way disease such as FEF25–75% suffer from wide variability, and others such as FEV3/FVC are also dependent on 
fixed segments of the expiratory curve26. Although qualitative assessment of expiratory curves has long been used 
to assess airflow obstruction, these changes are not readily apparent until the disease is far advanced. Parameter 
D, by partly representing the slow exponential decay in volume over the later part of the volume-time curve, is 
likely a reflection of small airway involvement and changes in elastic recoil of the lung. Using image matching, 
we show that Parameter D is strongly associated with PRMfSAD, a measure of non-emphysematous gas trapping18.
Since Salztman et al. tied the spirographic “kink”27, the angle between the steep and shallow parts of the 
expiratory curve, to emphysema and diffusing capacity of carbon monoxide (DLCO), multiple studies have 
quantified this angle. Kapp and colleagues found that the angle was progressively more acute with worsening 
airflow obstruction14. Topalovic et al. identified a threshold of 131◦ for the angle of collapse with a high specific-
ity for emphysema albeit with poor sensitivity28. Wang and group used angle of collapse ≤ 137° to differentiate 
asthma-COPD overlap subjects with significant emphysema15. Dominelli and group calculated the slope-ratio of 
the middle 20–80% of the expiratory curve to quantify its concavity, and to differentiate mild COPD from healthy 
older subjects29. The study included only symptomatic COPD and included elderly adults. Other measures have 
included the flow ratio expressed as a percentage of the instantaneous flow at 75 percent of the expired vital 
capacity (FR75)8, quantification of the curvature (kmax index)9, and shape factors at 25% and 50% of exhalation10. 
Most of these studies had small number of subjects and tied these metrics to FEV1. Two studies compared the new 
Figure 3. Representative images for a 54 year old African American male with a 34 pack-year smoking history 
who had significant symptom burden, with mMRC score of 3, and SGRQ score of 48. His lung function by 
traditional criteria was normal with FEV1/FVC of 0.72, and FEV1%predicted of 100.1%. Flow volume curve 
appears normal, however Parameter D was −0.08, which is abnormal. Computed tomography revealed 0.5% 
emphysema and 25% fSAD (highlighted in red). mMRC = Modified Medical Research Council Dyspnea 
Scale. SQRQ = St. George’s Respiratory Questionnaire. FEV1 = Forced Expiratory Volume in the first second. 
FVC = Forced Vital Capacity. fSAD = Functional small airway disease.
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metrics with emphysema but did not have measurement of small airway disease15,28. By testing our metrics against 
measures of structural airway and parenchymal disease on CT as well as with respiratory morbidity and mortality, 
we extend the literature by introducing robust metrics that add to the traditional measurements.
Our study has several strengths. We analyzed data from a large cohort of current and former smokers at risk 
for airflow obstruction, who were extensively phenotyped with spirometry and CT that were subject to stringent 
quality control. The new spirometry metrics were tested against structural lung disease on CT. We included a large 
number of African Americans, as well as women. We also note several limitations. The expiratory CT scans were 
acquired at FRC whereas the expiratory effort during spirometry ends in residual volume. However, by validating 
these forced expiratory measures in the possibly less sensitive tidal breath scans in COPDGene, our validation 
measures are likely stronger. We acknowledge that Parameter D could not be assessed in those with very severe 
disease (Supplemental Table 3), but this metric is likely to be more useful as an additive metric in those with mild 
disease. Mortality models were not adjusted for FEV1 as Parameter D and FEV1 are correlated due to the nature 
of measurements. However, we show that there is significant discordance between quartiles of Parameter D and 
GOLD stages, thus enabling identification of smokers in milder GOLD stages who have poor outcomes. Lastly, 
we analyzed subjects who were current and former smokers, and hence the results need to be validated in other 
populations at varying risk for airflow obstruction.
Conclusions
In summary, we developed several new and easily applicable metrics of mild airflow obstruction that in com-
bination with existing spirometry criteria have the potential to identify additional subjects with structural lung 
disease, and respiratory morbidity.
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